Recent Updates
Recently added Catalysts

Dry Eye Disease: 3 biotech companies with clinical-stage programmes

OphthalmologyOrphan cornerData as of 2026-09-04

Competitors3in the clinic
Median market cap$706Muniverse median $1.20B
Allocated capital$2.0B$3.6B competing
Phase 3 or filed03 mid, 0 early
Pure plays1this indication only
Capital rank96/299crowding rank 66

Dry Eye Disease sits in the orphan corner of the map: 3 developers, none of them large, with a median market cap of $706M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

BHC carries 71% of the $3.6B competing here, more than the other 2 companies combined.

$2.0B of allocated capital sits in Dry Eye Disease, 96th of 299 indications, and 1 of the 3 companies are pure plays that trade on this indication alone.

Companies developing drugs for Dry Eye Disease 3

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
BHCBausch Health CompaniesBL1107Phase 21$2.5BNo2No dated event
OCSOculis HoldinglicaminlimabPhase 21$706MYes1 31 Dec 2026
VNDAVanda PharmaceuticalsVSJ-110Phase 21$323MNo7 12 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. BHC holds 71% of the $3.6B competing in this indication.

Why Dry Eye Disease is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Dry Eye Disease has 3 competitors and a median of $706M.

Ophthalmology

Ophthalmology holds $17.0B of the map's capital, 2.5% of the total, spread across 9 indications and 13 companies. 6 of those indications have more than one company competing.

See every Ophthalmology indication on the map

Related indications in Ophthalmology

Diabetic Macular Edema4 companies · $1.3B · median $613MOrphan cornerHereditary Transthyretin Amyloidosis1 company · $1.1B · median $9.7BUncontestedMacular Edema1 company · $758M · median $2.3BUncontestedLeber Congenital Amaurosis2 companies · $600M · median $300MOrphan cornerWet Age-related Macular Degeneration4 companies · $3.5B · median $1.5BConcentrated betStargardt Disease2 companies · $3.6B · median $3.7BConcentrated betX-Linked Retinitis Pigmentosa1 company · $192M · median $768MUncontestedGeographic Atrophy3 companies · $4.0B · median $918MOrphan corner

Dry Eye Disease pipeline questions

Which biotech companies are developing drugs for Dry Eye Disease?

Bausch Health Companies (BHC, BL1107, Phase 2); Oculis Holding (OCS, licaminlimab, Phase 2); Vanda Pharmaceuticals (VNDA, VSJ-110, Phase 2). Those are the 3 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Dry Eye Disease.

How advanced is the Dry Eye Disease pipeline?

Of the 3 clinical-stage programmes in Dry Eye Disease, 0 are in Phase 3 or filed, 3 are in mid-stage development and 0 are in early-stage development.

Which company leads the Dry Eye Disease field?

BHC is the largest developer in Dry Eye Disease, holding 71% of the $3.6B of market capitalisation competing in the indication. The median competitor is worth $706M.

When is the next Dry Eye Disease catalyst?

The next dated catalyst in Dry Eye Disease is VNDA on 12 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map